<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875469</url>
  </required_header>
  <id_info>
    <org_study_id>20521</org_study_id>
    <nct_id>NCT03875469</nct_id>
  </id_info>
  <brief_title>Study to Test the Usability of a New Injector to Administer Contrast Media Into Humans for Diagnostic Purposes</brief_title>
  <acronym>PERCENT</acronym>
  <official_title>Performance of Centargo - A Novel Piston-based Injection System for High Throughput in Contrast-enhanced Computed Tomography (CE CT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates if a new medical device, which injects contrast media and flushing
      solution into humans to increase the visibility of images taken of the human body for
      diagnostic purposes, is easier to handle, quicker and cheaper than an older injector.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study compares an investigational injection system (Centargo) for computed tomography
      (CT) to a currently marketed injection system (Stellant MP) in terms of efficiency, cost,
      performance and user satisfaction (Part 1). In addition, the reliability of the new injection
      system Centargo is tested (Part 2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2019</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">March 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Setup time of CT systems</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change time for bottle/ bag containing contrast medium</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient setup time for the multi-patient set per day</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Teardown time of CT-system</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of multi-patient sets per day</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total cost for multi-patients set and disposables per patient and day</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reason for change of multi-patient syringe set for the injection of contrast media prior to expiration at 24 hours</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of unused contrast agent at teardown time</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of unused saline at teardown time</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow rate of contrast agent through the injector</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of contrast agent delivered through injector</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injector-generated pressure</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of automated system alerts</measure>
    <time_frame>1 day</time_frame>
    <description>Incl. alerts due to communication loss, pressure limiting, air detection (Centargo only) and a full waste container (Centrago only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographer satisfaction with contrast-media injector by study-related questionnaire</measure>
    <time_frame>Up to 4.5 months</time_frame>
    <description>Questionnaire contains 14 questions on injectors, disposables and software, pertaining to 5 levels of user satisfaction (´Very easy´ to ´Very hard´). Levels of user satisfaction from different questions are not combined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of errors requiring a CT-system reboot</measure>
    <time_frame>1 day</time_frame>
    <description>For Centargo only (Part 2)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">327</enrollment>
  <condition>Computed Tomography</condition>
  <arm_group>
    <arm_group_label>CT patients_Centargo_1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients referred for contrast-enhanced computed tomography in study part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-patients_Stellant_1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients referred for contrast-enhanced computed tomography in study part 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CT-patients_Centargo_2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients referred for contrast-enhanced computed tomography in study part 2 (includes all patients of Arm 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Centargo injector (BPI 1000045)</intervention_name>
    <description>Contrast-enhanced computer tomography conducted with Centargo injector</description>
    <arm_group_label>CT patients_Centargo_1</arm_group_label>
    <arm_group_label>CT-patients_Centargo_2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stellant MP injector</intervention_name>
    <description>Contrast-enhanced computer tomography conducted with Stellant MP injector</description>
    <arm_group_label>CT-patients_Stellant_1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects referred for contrast-enhanced computer tomography using a power
             injector

        Exclusion Criteria:

          -  Pregnant and lactating women

          -  Subjects with know hypersensitivity to iodinated contrast media

          -  Subjects with unacceptable renal function per local guidelines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medscan</name>
      <address>
        <city>Merrylands</city>
        <state>New South Wales</state>
        <zip>2160</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contrast-enhanced computed tomography (CECT)</keyword>
  <keyword>Injector</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

